ALDX - Aldeyra Therapeutics, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date: April 28, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $57.83M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.22 | 3.68%
Avg Daily Range (30 D): $0.06 | 4.34%
Avg Daily Range (90 D): $0.06 | 3.86%
Institutional Daily Volume
Avg Daily Volume: .59M
Avg Daily Volume (30 D): 1.33M
Avg Daily Volume (90 D): 1.24M
Trade Size
Avg Trade Size (Sh.): 149
Avg Trade Size (Sh.) (30 D): 347
Avg Trade Size (Sh.) (90 D): 234
Institutional Trades
Total Institutional Trades: 455
Avg Institutional Trade: $1.71M
Avg Institutional Trade (30 D): $1.71M
Avg Institutional Trade (90 D): $2.07M
Avg Institutional Trade Volume: .25M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.9M
Avg Closing Trade (30 D): $1.01M
Avg Closing Trade (90 D): $2.94M
Avg Closing Volume: 269.49K
 
News
Oct 8, 2026 @ 1:57 PM
Here's Why You Should Add LPCN Stock to Your Portf...
Source: Na
Oct 8, 2026 @ 1:49 PM
Ultragenyx to Sell Rare Pediatric Disease PRV for ...
Source: Na
Oct 7, 2026 @ 3:08 PM
ETON Stock Surges 108% in Six Months: Here's What ...
Source: Na
Oct 6, 2026 @ 1:30 PM
PCRX Expands Exparel Commercial Reach in Europe Th...
Source: Na
Sep 29, 2026 @ 1:06 PM
Acadia's Daybue Patent Allowance Extends U.S. Prot...
Source: Not Specified
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-.38 $-.09 $-.06
Diluted EPS $-.38 $-.09 $-.06
Revenue
Gross Profit
Net Income / Loss $-23.05M $-5.45M $-3.45M
Operating Income / Loss $-24.07M $-5.85M $-3.55M
Cost of Revenue
Net Cash Flow $3.85M $-24.95M $M
PE Ratio